$4.17
0.48% today
Nasdaq, Nov 11, 03:48 pm CET
ISIN
US23284F1057
Symbol
CTMX

CytomX Therapeutics, Inc. Stock price

$4.19
+0.83 24.70% 1M
+2.06 96.71% 6M
+3.16 306.80% YTD
+3.15 302.88% 1Y
+2.93 232.54% 3Y
-3.28 43.91% 5Y
-8.20 66.18% 10Y
-8.71 67.52% 20Y
Nasdaq, Closing price Mon, Nov 10 2025
+0.57 15.75%
ISIN
US23284F1057
Symbol
CTMX
Industry

Key metrics

Basic
Market capitalization
$709.9m
Enterprise Value
$551.8m
Net debt
positive
Cash
$158.1m
Shares outstanding
164.9m
Valuation (TTM | estimate)
P/E
11.3 | 139.6
P/S
5.0 | 7.5
EV/Sales
3.9 | 5.8
EV/FCF
negative
P/B
5.9
Financial Health
Equity Ratio
-0.4%
Return on Equity
-6,988.8%
ROCE
31.8%
ROIC
-784.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$141.1m | $95.1m
EBITDA
$44.7m | $22.4m
EBIT
$43.1m | $4.7m
Net Income
$48.0m | $5.0m
Free Cash Flow
$-77.7m
Growth (TTM | estimate)
Revenue
18.0% | -31.2%
EBITDA
486.6% | -16.1%
EBIT
654.1% | -81.1%
Net Income
333.0% | -84.5%
Free Cash Flow
10.0%
Margin (TTM | estimate)
Gross
-
EBITDA
31.7% | 23.6%
EBIT
30.6%
Net
34.0% | 5.2%
Free Cash Flow
-55.1%
More
EPS
$0.4
FCF per Share
$-0.5
Short interest
17.9%
Employees
120
Rev per Employee
$1.2m
Show more

Is CytomX Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

CytomX Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a CytomX Therapeutics, Inc. forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a CytomX Therapeutics, Inc. forecast:

Buy
86%
Hold
14%

Financial data from CytomX Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
141 141
18% 18%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 30 30
4% 4%
21%
- Research and Development Expense 68 68
18% 18%
48%
45 45
487% 487%
32%
- Depreciation and Amortization 1.57 1.57
17% 17%
1%
EBIT (Operating Income) EBIT 43 43
654% 654%
31%
Net Profit 48 48
333% 333%
34%

In millions USD.

Don't miss a Thing! We will send you all news about CytomX Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CytomX Therapeutics, Inc. Stock News

Positive
Seeking Alpha
about 6 hours ago
CytomX (CTMX) is advancing its ADC candidate CX-2051 in the oncological field. CX-2051 shows an impressive response rate and improved progression-free survival in heavily pretreated colorectal cancer patients, outperforming current therapies. Investment in CTMX is high risk and binary, but promising science and early clinical data support a speculative Buy for risk-tolerant investors.
Neutral
Seeking Alpha
4 days ago
CytomX Therapeutics, Inc. ( CTMX ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Chris Ogden - SVP & Chief Financial Officer Sean McCarthy - Chairman & CEO Conference Call Participants Edward Tenthoff - Piper Sandler & Co., Research Division Nabeel Nissar - Jefferies LLC, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Matthew Biegler - Opp...
Neutral
GlobeNewsWire
5 days ago
- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 supportive of ongoing Phase 1 combination study with KEYTRUDA® (pembrolizumab) in melanoma - - Company to host conference call today at 5 p.m. EST / 2 p.m.
More CytomX Therapeutics, Inc. News

Company Profile

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Head office United States
CEO Sean McCarthy
Employees 120
Founded 2010
Website cytomx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today